About Delcath Systems, Inc.
https://www.delcath.comDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
CEO
Gerard J. Michel MBA, MS
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-12-27 | Reverse | 1:700 |
| 2019-12-24 | Reverse | 1:700 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:983.01K
XSU.TO
Weight:0.01%
Shares:735.27K
IWM
Weight:0.01%
Shares:735.27K
Summary
Showing Top 3 of 56
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ROSALIND ADVISORS, INC.
Shares:3.3M
Value:$34.26M
BLACKROCK, INC.
Shares:1.77M
Value:$18.36M
VANGUARD GROUP INC
Shares:1.66M
Value:$17.2M
Summary
Showing Top 3 of 131
About Delcath Systems, Inc.
https://www.delcath.comDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $20.56M ▼ | $18.33M ▲ | $830K ▼ | 4.04% ▼ | $0.02 ▼ | $467K ▼ |
| Q2-2025 | $24.16M ▲ | $18.25M ▲ | $2.7M ▲ | 11.16% ▲ | $0.08 ▲ | $2.62M ▲ |
| Q1-2025 | $19.78M ▲ | $16.3M ▲ | $1.07M ▲ | 5.4% ▲ | $0.03 ▲ | $709K ▼ |
| Q4-2024 | $15.1M ▲ | $9.94M ▼ | $-3.4M ▼ | -22.5% ▼ | $-0.11 ▼ | $10.48M ▲ |
| Q3-2024 | $11.2M | $10.82M | $1.86M | 16.64% | $0.06 | $-1.16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $88.91M ▲ | $124.3M ▲ | $9.45M ▼ | $114.85M ▲ |
| Q2-2025 | $81M ▲ | $116.88M ▲ | $11.89M ▲ | $104.99M ▲ |
| Q1-2025 | $58.9M ▲ | $87.32M ▲ | $7.09M ▼ | $80.23M ▲ |
| Q4-2024 | $53.23M ▲ | $76.59M ▲ | $7.84M ▼ | $68.75M ▲ |
| Q3-2024 | $13.99M | $31.68M | $23.11M | $8.57M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $830K ▼ | $4.77M ▼ | $-466K ▼ | $3.1M ▼ | $7.39M ▼ | $4.31M ▼ |
| Q2-2025 | $2.7M ▲ | $7.29M ▲ | $-415K ▲ | $14.64M ▲ | $21.64M ▲ | $6.89M ▲ |
| Q1-2025 | $1.07M ▲ | $2.2M ▲ | $-25.15M ▼ | $3.25M ▼ | $-19.64M ▼ | $2.06M ▲ |
| Q4-2024 | $-3.4M ▼ | $-1.01M ▲ | $-15.23M ▼ | $40.38M ▲ | $24.1M ▲ | $-1.24M ▲ |
| Q3-2024 | $1.86M | $-3.64M | $-697K | $-2.14M | $-6.47M | $-3.86M |
Revenue by Products
| Product | Q1-2023 | Q4-2023 | Q3-2023 | Q2-2023 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product and Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Gerard J. Michel MBA, MS
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-12-27 | Reverse | 1:700 |
| 2019-12-24 | Reverse | 1:700 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:983.01K
XSU.TO
Weight:0.01%
Shares:735.27K
IWM
Weight:0.01%
Shares:735.27K
Summary
Showing Top 3 of 56
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ROSALIND ADVISORS, INC.
Shares:3.3M
Value:$34.26M
BLACKROCK, INC.
Shares:1.77M
Value:$18.36M
VANGUARD GROUP INC
Shares:1.66M
Value:$17.2M
Summary
Showing Top 3 of 131